Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy .
F-star Therapeutics, Inc.April 19, 2021 GMT
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model
SB 11285 is a Second Generation STING Agonist Delivered Intravenously
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced the publication of a new study, conducted by Yale University and F-star, of its second generation STING agonist, SB 11285, in the current issue of
F-star Therapeutics, Inc.: F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
Study Confirms F-star s Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and Activation
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021, a potentially best-in-class tetravalent bispecific antibody targeting both CD137 and PD-L1 will be presented in a poster at the 2021 American Academy of Cancer Research, taking place virtually from April 10-15 and May 17-21. Poster #1864, entitled FS222, a Tetravalent Bispecific Antibody Targeting CD137 and PD-L1, is Designed for Optimal CD137 Interactions Resulting in Potent T cell Activation Without Toxicity will be available via on-demand viewing starting today, April 10, at 8:30 a.m. ET.
(0)
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised its option to develop an additional bispecific program under the ongoing collaboration with F-star.
This is the third option to license a preclinical program that Merck KGaA, Darmstadt, Germany has exercised in the ongoing collaboration with F-star. Merck KGaA, Darmstadt, Germany and F-star originally entered into a collaboration agreement in 2019 with the first option to license. In July 2020, Merck KGaA, Darmstadt, Germany brought the second program from the collaboration into its pipeline, and today has exercised its third option, taking over future development and commercialization of the program. An undisclosed option exercise payment will be
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021and the Oppenheimer & Co 31st Annual Healthcare Conference. Both events will take place virtually. Details are as follows: H.C. Wainwright
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 .
F-star Therapeutics, Inc.January 20, 2021 GMT
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 20-year term of protection, is expected to be June 2037.